Why LifeStance Health Group, Inc.’s (LFST) Stock Is Up 10.61%
As of Monday, August 10, LifeStance Health Group, Inc.’s LFST share price has surged by 10.61%, which has investors questioning if this is right time to sell.Jenna Brashear
Stock Evaluator: LifeStance Health Group, Inc. (LFST)
LifeStance Health Group, Inc. LFST
$12.60
0.24
1.94%
September 1, 2026 4:00:00 PM
EST
Volume: 3,465,802
After Hours: $120.37
0.15
|
0.12%
November 10, 2021 7:59 PM
EST
Volume: 72,713
USD
NASD | DELAYED PRICE
| SECTOR | INDUSTRY |
| Health Care | Health Care Providers & Services |
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
LifeStance Health Group, Inc., through its subsidiaries, provides outpatient mental health services to children, adolescents, adults, and geriatrics in the United States. The company offers patients a multidisciplinary suite of mental health services, psychiatric evaluations and treatment, psychological, and neuropsychological testing, as well as individual, family, and group therapy. It also treats a range of mental health conditions, including anxiety, depression, bipolar disorder, eating disorders, psychotic disorders, and post-traumatic stress disorder. In addition, the company operates an outpatient mental health platform, as well as offers patient care virtually through its online delivery platform or in-person at its centers. LifeStance Health Group, Inc. was founded in 2017 and is headquartered in Scottsdale, Arizona.
Commentary & Analysis
Why LifeStance Health Group, Inc.’s (LFST) Stock Is Up 12.08%
As of Monday, August 10, LifeStance Health Group, Inc.’s LFST share price has surged by 12.08%, which has investors questioning if this is right time to sell.Jenna Brashear
What You Need to Know About LifeStance Health Group, Inc.'s Q3 Earnings
LifeStance Health Group, Inc.'s fiscal Q3 earnings report was released on Thursday, August 06. Let's dive in to see if (LFST) missed or beat analyst's expectations.Michael Rose
Which Is a Better Investment, LifeStance Health Group, Inc. or NeoGenomics, Inc. Stock?
Learn more about whether LifeStance Health Group, Inc. or NeoGenomics, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.Tudor Pop
Is LifeStance Health Group, Inc. (LFST) Overvalued?
We dive into why LifeStance Health Group, Inc. (LFST) could be considered overvalued on 2026-07-30, based on AAII’s Value Score and Grade.Jenna Brashear
Financial Summary
| Share Statistics | LFST | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $4,813.9 | $1,790.6 | 67% |
|
| Shares Out (Mil) | 387.3 | 71.5 | 86% |
|
| Institutional Ownership | 95.5% | 86.0% | 67% |
|
| Float (Mil) | 249.0 | 55.7 | 77% |
|
| Beta | 1.20 | 0.75 | 70% |
|
| Avg Daily Volume (000s) | 3,203 | 509 | 89% |
|
| Price Change (52-week) |
129.9% | 79.4% | 95% |
|
| Growth | LFST | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 30.4% | 10.7% | 90% |
|
| Net Income (5yr) | 17.7% | (0.5%) | 69% |
|
| EPS (5yr) | 15.1% | 3.0% | 57 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | 11.4% | (17.5%) | 70% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 5 | 5 | 5 | |
| Current EPS | $0.100 | $0.396 | $0.531 | |
| Month Ago EPS | $0.074 | $0.311 | $0.392 | |
| # Rev Up | 0 | 1 | 1 | |
| # Rev Down | 1 | 0 | 0 | |
| Three Months Ago EPS | $0.077 | $0.322 | $0.405 | |
| Year/Year Chg | 66.7% | 1,880% | 3,465% | |
| Financials | LFST | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $1,585 | $1,490 | 57% |
|
| Net Income (TTM) (Mil) | $51 | $24 | 55% |
|
| EPS (TTM) | $0.131 | $0.200 | 44% |
|
| Operating Cash Flow (TTM) (Mil) | $218 | $151 | 60% |
|
| Net Cash Flow (TTM) (Mil) | $37 | $8 | 67% |
|
| Long-Term Debt (Q1) (Mil) | $413 | $331 | 57% |
|
| Enterprise Value (Q1) (Mil) | $5,012 | $2,334 | 62% |
|
| Valuation | LFST | Industry Median |
Percentile (All Stocks) |
|
| P/B | 3.26 | 2.95 | 67% |
|
| P/E | 97.7 | 25.6 | 93% |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | 6.5 | 1.1 | 91% |
|
| Ratios | LFST | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 33.6% | 28.3% | 40% |
|
| Net Margin | 3.2% | 1.3% | 42% |
|
| ROA | 2.3% | 2.2% | 57% |
|
| ROE | 3.4% | 6.8% | 41% |
|
| Liabilities to Assets | 32.3% | 58.6% | 23% |
|
| F-Score | 8 | 5 | 93% |
|
Passing Stock Screens
As of 9/1/2026, from a list of 60 stock screening strategies,
FACTOR STRATEGY
Est Rev: Top 30 Up
Factors: Earnings Estimates
Introduction to the use of earnings estimates.
| Performance Since Inception: | 21.4% |
| +/- S&P 500: | +13.9 |
FACTOR STRATEGY
Est Rev: Up 5% Screen
Factors: Earnings Estimates
Introduction to the use of earnings estimates.
| Performance Since Inception: | 22.6% |
| +/- S&P 500: | +15.1 |
GURU STRATEGY
Kirkpatrick Growth Screen
Factors: Momentum, Growth
Investing model outlined in Charles Kirkpatrick's book, Beat the Market: Invest by Knowing What Stocks to Buy and What Stocks to Sell.
| Performance Since Inception: | 14.4% |
| +/- S&P 500: | +6.9 |
